Navigation Links
Study identifies new approach to improving treatment for MS and other conditions
Date:5/17/2013

(SACRAMENTO, Calif.) Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS.

The findings of the research study, published online today in the journal EMBO Molecular Medicine could have therapeutic applications for MS as well as cerebral palsy and leukodystrophies, all disorders associated with loss of white matter, which is the brain tissue that carries information between nerve cells in the brain and the spinal cord.

The target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord. The mitrochronical TSPO is located on the outer surface of mitochondria, cellular structures that supply energy to the cells. Damage to the fatty coating, or myelin, slows the transmission of the nerve signals that enable body movement as well as sensory and cognitive functioning.

The scientists identified mitochondrial TSPO as a potential therapeutic target when mice that had symptoms of MS improved after being treated with the anti-anxiety drug etifoxine, which interacts with mitochondrial TSPO. When etifoxine, a drug clinically available in Europe, was administered to the MS mice before they had clinical signs of disease, the severity of the disease was reduced when compared to the untreated lab animals. When treated at the peak of disease severity, the animals' MS symptoms improved.

"Etifoxine has a novel protective effect against the loss of the sheath that insulates the nerve fibers that transmit the signals from brain cells," said Wenbin Deng, principal investigator of the study and associate professor of biochemistry and molecular medicine at UC Davis.

"Our discovery of etifoxine's effects on an MS animal model suggests that mitochondrial TSPO represents a potential therapeutic target for MS drug development," said Deng.

"Drugs designed to more precisely bind to mitochondrial TSPO may help repair the myelin sheath of MS patients and thereby even help restore the transmission of signals in the central nervous system that enable normal motor, sensory and cognitive functions," he said.

Deng added that better treatments for MS and other demyelinating diseases are needed, especially since current FDA-approved therapies do not repair the damage of immune attacks on the myelin sheath.

The UC Davis research team hopes to further investigate the therapeutic applications of mitochondrial TSPO in drug development for MS and other autoimmune diseases. To identify more efficacious and safer drug candidates, they plan to pursue research grants that will enable them to test a variety of pharmacological compounds that bind to mitochondrial TSPO and other molecular targets in experimental models of MS and other myelin diseases.

The journal paper is entitled, "A TSPO ligand is protective in a mouse model of multiple sclerosis."


'/>"/>

Contact: Charles Casey
charles.casey@ucdmc.ucdavis.edu
916-734-9048
University of California - Davis Health System
Source:Eurekalert

Related medicine news :

1. Study: Peer-referral programs can increase HIV-testing in emergency departments
2. New study pinpoints biochemical mechanism underlying fibrosis following glaucoma surgery
3. Study: Patient openness to research can depend on race and sex of study personnel
4. The Institute of Regenerative & Molecular Orthopedics Applauds Newly Released Study on Platelet-Rich Plasma
5. Study suggests new role for ECMO in treating patients with cardiac arrest and profound shock
6. Bel Marra Health Reports on a New Study Revealing a Natural Remedy for Hypertension, Insomnia, and Aging
7. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
8. New Study Reveals that Fitness Levels May Affect Attention Span, Making Weight Loss, Such as With Prescopodene, Helpful With Promoting Concentration
9. New study recommends using active videogaming (exergaming) to improve childrens health
10. Study: Brain makes call on which ear is used for cell phone
11. 2013 Is the Year of Mobility in Government: Study Shows Media Landscape Shifting in Government Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... PrideStaff, a national, ... Franchise Development, Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide ... of top business leaders from across the globe, provides viewers an opportunity to ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... offering asset protection and financial planning services to families and business owners in ... event aimed at supporting children with developmental disabilities. , The Lakemary Center is ...
(Date:1/18/2017)... ... , ... Dr. Farhan Qureshi is an esteemed dentist who offers a full ... has two convenient office locations in Alexandria and Arlington, Virginia. Recently, Find Local Dentists ... area. This award confirms the fact that Dr. Qureshi’s patients have left highly ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... company, launched a new website for its Center for Biosimilars, announced Michael J. ... the latest developments in the field of biosimilars through thought leader interaction in, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Active Brake Technology (ABT), an innovative braking system that allows skaters of all ... addresses one of the biggest concerns of beginner and intermediate skaters – learning ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/18/2017)... TOKYO , Jan. 18, 2017  Astellas ... , "Astellas" ) today announced its participation in ... access to non-communicable disease (NCD) prevention, diagnostics and ... with 21 other leading pharmaceutical companies and in ... Union for International Cancer Control (UICC), Astellas will ...
(Date:1/17/2017)... , Jan. 17, 2017 Precision medicine ... for the treatment of disease. The approach allows ... to a therapy. The approach studies the individual ... lifestyle and environment. In January 2015, Precision Medicine ... to all diseases with more than one million ...
Breaking Medicine Technology: